Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)
NCT ID: NCT02697201
Last Updated: 2021-07-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
25 participants
INTERVENTIONAL
2016-07-31
2021-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Mitochondria are cellular structures that are responsible for turning nutrients from food, into the energy that our cells run on. As a result, mitochondria are known as "the powerhouse of the cell." Mitochondria are dynamic organelles that can move within a cell to the areas where they are needed, and can fuse together to form large, string-like, tubular networks or divide into small spherical structures. The name of this process is "mitochondrial dynamics" and the process keeps the cells healthy. However, when more food is consumed compared to the amount of energy burned, mitochondria may become overloaded and dysfunctional resulting in a leak of partially metabolized nutrients that can interfere with the ability of insulin to communicate within the cell. This may be a way for the cells to prevent further uptake of nutrients until the current supply has been exhausted. However, long term overload of the mitochondria may cause blood sugar levels to rise and lead to the development of type 2 diabetes.
This study will provide information about the relationship between mitochondrial dynamics, insulin resistance and type 2 diabetes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus
NCT00445627
Glucolipotoxicity and Type 2 Diabetes
NCT01375270
The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans
NCT06972407
Regulation of Tissue Lipolysis by Insulin in Type 2 Diabetes
NCT01680133
The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)
NCT01449019
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intralipid Infusion, then Saline
Participants in this arm will first receive a lipid infusion. Then 4 weeks later the saline infusion.
Intralipid
0.55 ml/kg/h
Saline
0.55 ml/kg/h for
Saline Infusion, then Intralipid
Participants in this arm will first receive a saline infusion. Then 4 weeks later the lipid infusion.
Intralipid
0.55 ml/kg/h
Saline
0.55 ml/kg/h for
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intralipid
0.55 ml/kg/h
Saline
0.55 ml/kg/h for
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sedentary
* Normal glucose tolerance
* BMI \<25 kg/m2
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pennington Biomedical Research Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John Kirwan
Executive Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John P Kirwan, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Pennington Biomedical Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Axelrod CL, Fealy CE, Erickson ML, Davuluri G, Fujioka H, Dantas WS, Huang E, Pergola K, Mey JT, King WT, Mulya A, Hsia D, Burguera B, Tandler B, Hoppel CL, Kirwan JP. Lipids activate skeletal muscle mitochondrial fission and quality control networks to induce insulin resistance in humans. Metabolism. 2021 Aug;121:154803. doi: 10.1016/j.metabol.2021.154803. Epub 2021 Jun 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-1311
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.